{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:02Z","timestamp":1793502722248,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-019-01067-3","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T20:45:17Z","timestamp":1550609117000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Eravacycline: A Review in Complicated Intra-Abdominal Infections"],"prefix":"10.1007","volume":"79","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"issue":"1","key":"1067_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/sur.2016.261","volume":"18","author":"JE Mazuski","year":"2017","unstructured":"Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdombinal infection. Surg Infect. 2017;18(1):1\u201376.","journal-title":"Surg Infect."},{"key":"1067_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","volume":"12","author":"M Sartelli","year":"2017","unstructured":"Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29.","journal-title":"World J Emerg Surg."},{"issue":"5","key":"1067_CR3","first-page":"344","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola CL. The antibiotic resistance crisis. Part 2: management strategies and new agents. Pharm Therap. 2015;40(5):344\u201352.","journal-title":"Pharm Therap."},{"issue":"10","key":"1067_CR4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","volume":"23","author":"H Wright","year":"2017","unstructured":"Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23(10):704\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"1067_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","volume":"109","author":"F Prestinaci","year":"2015","unstructured":"Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathogens Glob Health. 2015;109(7):309\u201318.","journal-title":"Pathogens Glob Health."},{"issue":"10","key":"1067_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","volume":"15","author":"I Karaiskos","year":"2014","unstructured":"Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351\u201370.","journal-title":"Expert Opin Pharmacother"},{"key":"1067_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13017-016-0089-y","volume":"11","author":"M Sartelli","year":"2016","unstructured":"Sartelli M, Weber DG, Rupp\u00e9 E, et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg. 2016;11:33.","journal-title":"World J Emerg Surg."},{"issue":"2","key":"1067_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1021\/jm201465w","volume":"55","author":"X-Y Xiao","year":"2012","unstructured":"Xiao X-Y, Hunt DK, Zhou J, et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012;55(2):597\u2013605.","journal-title":"J Med Chem."},{"issue":"2","key":"1067_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1021\/jm201467r","volume":"55","author":"RB Clark","year":"2012","unstructured":"Clark RB, Hunt DK, He M, et al. Fluorocyclines. 2. Optimization of the C-9 side chain for antibacterial activity and oral efficacy. J Med Chem. 2012;55(2):606\u201322.","journal-title":"J Med Chem."},{"issue":"5","key":"1067_CR10","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1128\/AAC.06187-11","volume":"56","author":"TH Grossman","year":"2012","unstructured":"Grossman TH, Starosta AL, Fyfe C, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56(5):2559\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"1067_CR11","unstructured":"Tetraphase Pharmaceuticals Inc. Xerava (Eravacycline): US prescribing information. 2018. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 21 Oct 2018."},{"issue":"5","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567\u201388.","journal-title":"Drugs."},{"key":"1067_CR13","unstructured":"European Medicines Agency. Xerava (Eravacycline): summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 1 Nov 2018."},{"issue":"5","key":"1067_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1515\/hsz-2013-0292","volume":"395","author":"F Nguyen","year":"2014","unstructured":"Nguyen F, Starosta AL, Arenz S, et al. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014;395(5):559\u201375.","journal-title":"Biol Chem"},{"issue":"5","key":"1067_CR15","doi-asserted-by":"publisher","first-page":"e02206","DOI":"10.1128\/AAC.02206-17","volume":"62","author":"DR Snydman","year":"2018","unstructured":"Snydman DR, McDermott LA, Jacobus NV, et al. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2018;62(5):e02206\u201317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1067_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.diagmicrobio.2017.12.013","volume":"91","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Baxter MR, Adam HJ, et al. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis. 2018;91(1):55\u201362.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"1067_CR17","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59(3):1802\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1067_CR18","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548\u201358.","journal-title":"Antimicrob Agents Chemother"},{"key":"1067_CR19","unstructured":"Olesky M, Morrissey I, Hawser S, et al. In vitro activity of eravacycline and comparators against resistant Gram-negative isolates collected in 2016 from patients in Europe. [abstract no. P0099]. In: 28th ECCMID. 2018."},{"key":"1067_CR20","unstructured":"Lawrence K, Olesky M, Fyfe C, et al. Global surveillance of in vitro activity of eravacycline and comparators against Enteroacteriaceae, Stenotrophomonas maltophilia, Staphylococcus aureus and Enterococcus spp. collected during 2016. [abstract no. P0101]. In: 28th ECCMID. 2018."},{"key":"1067_CR21","unstructured":"Morrissey I, Bassetti M, Magnet S, et al. In vitro activity of eravacycline and comparators against Staphylococcus aureus and Enterococci, including methicillin-resistant and vancomycin-resistant subgroups, collected from European hospitals in 2015. [abstract no. P1358]. In: 27th ECCMID. 2017."},{"key":"1067_CR22","unstructured":"Morrissey I, Bassetti M, Magnet S, et al. In vitro activity of eravacycline and comparators against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae, including carbapenem-resistant and ESBL phenotype subgroups, collected from European hospitals in 2015. [abstract no. P1260]. In: 27th ECCMID. 2017."},{"key":"1067_CR23","doi-asserted-by":"crossref","unstructured":"Olesky M, Bassetti M, Corey R, et al. In vitro global surveillance of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, including multidrug-resistant (MDR) isolates, over a three-year period (2013\u201315). [abstract no. 20]. In: ASM\/ESCMID conference on drug development to meet the challenges of antimicrobial resistance. 2017.","DOI":"10.1093\/ofid\/ofw172.1373"},{"key":"1067_CR24","doi-asserted-by":"crossref","unstructured":"Olesky M, Bassetti M, Corey R, et al. In vitro global surveillance of eravacycline and comparators against Staphylococcus spp. and Enterococcus spp. over a three-year period (2013-15) [abstract no. 22]. In: ASM\/ESCMID conference on drug development to meet the challenges of antimicrobial resistance. 2017.","DOI":"10.1093\/ofid\/ofw172.1368"},{"key":"1067_CR25","unstructured":"Bouchillon S, Hawser S, Monti F, et al. Surveillance of the in vitro activity of eravacycline and comparators against clinical isolates from the US from 2013-2016. [abstract no. Global-MO11]. In: Surgical Infection Society Meeting. 2018."},{"key":"1067_CR26","unstructured":"Efimova E, Bassetti M, Hawser S, et al. Eravacycline in vitro activity against European clinical isolates obtained in 2016 from urinary and gastrointestinal sources, including drug resistant pathogens. [abstract no. P0100]. In: 28th ECCMID. 2018."},{"issue":"1","key":"1067_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","volume":"51","author":"H Seifert","year":"2018","unstructured":"Seifert H, Stefanik D, Sutcliffe JA, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51(1):62\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1067_CR28","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1128\/AAC.00436-16","volume":"60","author":"DM Livermore","year":"2016","unstructured":"Livermore DM, Mushtaq S, Warner M, et al. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(6):3840\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1067_CR29","unstructured":"Rhoads DD, Bajaksouzian S, Abdelhamed AM, et al. Activity of eravacycline against carbapenem resistant Enterobacteriaceae and Acinetobacter baumannii [poster]. In: ASM Microbe. 2017."},{"issue":"8","key":"1067_CR30","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1128\/AAC.00366-16","volume":"60","author":"ML Monogue","year":"2016","unstructured":"Monogue ML, Thabit AK, Hamada Y, et al. Antibacterial efficacy of eravacycline in vivo against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 2016;60(8):5001\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1067_CR31","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1128\/AAC.04354-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman TH, Murphy TM, Slee AM, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015;59(5):2567\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1067_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ijantimicag.2018.01.001","volume":"51","author":"AK Thabit","year":"2018","unstructured":"Thabit AK, Monogue ML, Newman JV, et al. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic\/pharmacodynamic analysis. Int J Antimicrob Agents. 2018;51(5):727\u201332.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"1067_CR33","doi-asserted-by":"publisher","first-page":"6989","DOI":"10.1128\/AAC.01646-16","volume":"60","author":"C Fyfe","year":"2016","unstructured":"Fyfe C, LeBlanc G, Close B, et al. Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1. Antimicrob Agents Chem. 2016;60(11):6989\u201390.","journal-title":"Antimicrob Agents Chem."},{"key":"1067_CR34","unstructured":"El-Bouseary M, Tyrrell J, Walsh TR, et al. Comparative in vitro activity of eravacycline, a novel fluorocycline, against mcr-1-positive Escherichia coli and Klebsiella pneumoniae. [abstract no. P058]. In: 27th ECCMID. 2017."},{"issue":"7","key":"1067_CR35","doi-asserted-by":"publisher","first-page":"e00250-17","DOI":"10.1128\/AAC.00250-17","volume":"61","author":"M Zhao","year":"2017","unstructured":"Zhao M, Lepak AJ, Marchillo K, et al. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(7):e00250-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1067_CR36","unstructured":"VanScoy BD, Lakota EA, Adams J, et al. Pharmacokinetics-pharmacodynamics (PK-PD) of efficacy for eravacycline against Escherichia coli in an in vitro infection model. [abstract no. 24]. In: ASM\/ESCMID conference on drug development to meet the challenges of antimicrobial resistance. 2017."},{"key":"1067_CR37","unstructured":"Horn PT, Redican S, Wei X, et al. Eravacycline does not prolong corrected QT intervals in a thorough QT study conducted in healthy subjects [abstract no. P0310]. In: 24th ECCMID. 2014."},{"issue":"11","key":"1067_CR38","doi-asserted-by":"publisher","first-page":"e01174-18","DOI":"10.1128\/AAC.01174-18","volume":"62","author":"JV Newman","year":"2018","unstructured":"Newman JV, Zhou J, Izmailyan S, et al. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother. 2018;62(11):e01174-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1067_CR39","doi-asserted-by":"crossref","unstructured":"Horn P, Redican S, Olesky M. Pharmacokinetics (PK) of eravacycline in subjects with renal or hepatic impairment compared to healthy subjects. [abstract no. 1829]. In: IDWeek. 2017.","DOI":"10.1093\/ofid\/ofx163.1359"},{"issue":"3","key":"1067_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE1) trial: a randomized clinical trial. JAMA Surg. 2017;152(3):224\u201332.","journal-title":"JAMA Surg"},{"key":"1067_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029\/5250914","author":"JS Solomkin","year":"2018","unstructured":"Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis. 2018. \n                    https:\/\/doi.org\/10.1093\/cid\/ciy1029\/5250914\n                    \n                  .","journal-title":"Clin Infect Dis."},{"issue":"4","key":"1067_CR42","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","volume":"58","author":"JS Solomkin","year":"2014","unstructured":"Solomkin JS, Ramesh MK, Cesnauskas G, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(4):1847\u201354.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1067_CR43","first-page":"291","volume":"1","author":"A Fonte","year":"2018","unstructured":"Fonte A, Lawrence K, Izmailyan S, et al. Efficacy of eravacycline in obese patients: pooled analsysis of IGNITE1 and IGNITE4 [abstract no. 448 plus poster]. J Am Coll Clin Pharm. 2018;1(2):291.","journal-title":"J Am Coll Clin Pharm."},{"key":"1067_CR44","unstructured":"Ditch K, Newman J, Izmailyan S, et al. Microbiological efficacy of eravacycline against Enterobacteriaceae and Acinetobacter, including MDR isolates: a pooled analysis from IGNITE1 and IGNITE4, two phase 3 trials of complicated intra-abdominal infection [abstract no. 629 plus poster]. In: ASM Microbe. 2018."},{"key":"1067_CR45","unstructured":"Michaud M, Hoffman-Roberts H, Marsh A. Evaluation of patients with complicated intra-abdominal infections (cIAI) and concomitant bacteremia (CB) from IGNITE1: a phase 3 study to evaluate the efficacy and safety of eravacycline (ERV) versus ertapenem (ETP) in complicated intra-abdominal infections (cIAI) [abstract no. 426]. In: ASM Microbe. 2016."},{"key":"1067_CR46","doi-asserted-by":"crossref","unstructured":"Lawrence K, Olesky M, Izmailyan S, et al. Efficacy of eravacycline in secondary bacteremia: a post hoc analysis of two phase 3 studies of complicated intra-abdominal infection [abstract no. 1978 plus poster]. In: ID Week. 2018.","DOI":"10.1093\/ofid\/ofy210.1634"},{"issue":"2","key":"1067_CR47","first-page":"290","volume":"1","author":"A Fonte","year":"2018","unstructured":"Fonte A, Lawrence K, Izmailyan S, et al. Effect of renal function in IGNITE1 and IGNITE4: two phase 3 studies to evaluate the efficacy and safety of eravacycline [abstract no. 447 plus poster]. J Am Coll Clin Pharm. 2018;1(2):290\u20131.","journal-title":"J Am Coll Clin Pharm."},{"key":"1067_CR48","doi-asserted-by":"crossref","unstructured":"Efimova E, Olesky M, Izmailyan S, et al. Pooled analysis of safety data from phase 2 and 3 clinical trials evaluating eravacycline in complicated intra-abdominal infections [abstract no. 1976 plus poster]. In: ID Week. 2018.","DOI":"10.1093\/ofid\/ofy210.1632"},{"key":"1067_CR49","unstructured":"Wyeth Pharmaceuticals Inc. TYGACIL\u00ae (tigecylcine) for injection for intravenous use: US prescribing information. 2017. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 14 Jan 2019."}],"updated-by":[{"DOI":"10.1007\/s40265-019-01117-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01067-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01067-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01067-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:15:15Z","timestamp":1582139715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01067-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01067-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"20 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Eravacycline: A Review in Complicated Intra-Abdominal Infections, written by Lesley J. Scott, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lesley Scott is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}